Bernát Ladislav, Hrušák Daniel
Department of Maxillofacial Surgery (Head: Dr. Daniel Hrušák, Ph.D.), Charles University Hospital Pilsen, Alej Svobody 80, 304 60 Plzen, Czech Republic.
Department of Maxillofacial Surgery (Head: Dr. Daniel Hrušák, Ph.D.), Charles University Hospital Pilsen, Alej Svobody 80, 304 60 Plzen, Czech Republic.
J Craniomaxillofac Surg. 2014 Jun;42(4):356-61. doi: 10.1016/j.jcms.2013.09.009. Epub 2013 Sep 27.
Hypothyroidism is not commonly considered as a complication of radiotherapy to the head and neck region. The purpose of this retrospective study was to determine the frequency of thyroid dysfunction in patients after radiotherapy, to compare thyroid hormone levels in irradiated patients with Control group and to predict development of thyroid hypofunction in time.
Thyroid function was measured by means of thyroid stimulating hormone (TSH), free thyroxine (FT4) and free triiodthyronine (FT3) in 43 patients who had nonthyroid head-neck carcinomas treated by radiotherapy or radiotherapy in combination with other modalities. These data were compared with hormone levels of 40 Control group patients treated solely by surgery.
Hypothyroidism was found in 35% of irradiated patients. In comparison with Control group there were significant differences between TSH and FT4 levels, difference between FT3 levels was insignificant. A correlation between hormone levels and follow-up was detected.
Our results indicate that hypothyroidism is a frequent late side effect of radiotherapy to head and neck. Lifelong monitoring of thyroid function appears to be justified when radiotherapy is a part of treatment protocol.
甲状腺功能减退通常不被视为头颈部放疗的并发症。本回顾性研究的目的是确定放疗后患者甲状腺功能障碍的发生率,比较放疗患者与对照组的甲状腺激素水平,并及时预测甲状腺功能减退的发生。
对43例接受放疗或放疗联合其他治疗方式的非甲状腺头颈部癌患者,通过促甲状腺激素(TSH)、游离甲状腺素(FT4)和游离三碘甲状腺原氨酸(FT3)来测量甲状腺功能。将这些数据与40例仅接受手术治疗的对照组患者的激素水平进行比较。
35%的放疗患者出现甲状腺功能减退。与对照组相比,TSH和FT4水平存在显著差异,FT3水平差异不显著。检测到激素水平与随访之间存在相关性。
我们的结果表明,甲状腺功能减退是头颈部放疗常见的晚期副作用。当放疗是治疗方案的一部分时,对甲状腺功能进行终身监测似乎是合理的。